| Adenocarcinoma | 42, 116 |
| Adenomatoid tumor | 166 |
| Adrenal gland | 35 |
| Adrenalectomy | 35 |
| Aged | 106 |
| Anesthesia | 111 |
| Angiomyolipoma | 84 |
| Apparent diffusion coefficient value | 28 |
| Atypical pathologies | 35 |
| Azotemia | 57 |
| BCG | 20 |
| Benign tumor | 166 |
| Biological markers | 15 |
| Bladder | 68 |
| Bladder cancer | 20, 50, 116, 144 |
| Cancer | 1 |
| Clinicopathological features | 144 |
| Congenital adrenal hyperplasia | 80 |
| Database | 72 |
| De Ritis ratio | 15 |
| DISCERN | 156 |
| Diagnosis | 156 |
| Drop metastasis | 46 |
| Epididymal adenocarcinoma | 123 |
| Epididymal cancer | 123 |
| Fluoroquinolone | 106 |
| Fosfomycin | 106 |
| Hematuria | 161 |
| High grade | 20 |
| Hydronephrosis | 57 |
| Infertility | 80 |
| JAMA | 156 |
| Kidney tumors | 76 |
| Laparoscopic surgery | 94 |
| Laparoscopy | 120 |
| Local | 111 |
| Lower urinary tract symptoms | 42 |
| Lung cancer | 144 |
| Magnetic resonance imaging | 28 |
| Metastasis | 126 |
| Monoclonal antibodies | 1 |
| Mortality | 150 |
| MTOR inhibitors | 84 |
| Multiparametric magnetic resonance imaging | 100 |
| Nephrectomy | 94, 150 |
| Nursing care | 50 |
| Oligometastatic prostate cancer | 62 |
| Oncocytic | 46 |
| Oncological outcome | 144 |
| Orchiectomy | 126 |
| Organ-sparing surgery | 89 |
| Overall survival | 150 |
| Papillary RCC | 46 |
| Paratesticular masses | 123 |
| Partial cystectomy | 161 |
| Partial nephrectomy | 76, 120 |
| Partial orchiectomy | 89 |
| Pathological outcomes | 138 |
| Patient outcome | 94 |
| PET imaging | 129 |
| PET/CT | 80 |
| PI-RADSv2.1 | 28 |
| Postponement time-period for surgery (PTP) | 150 |
| Primary bladder cancer | 15 |
| Prognosis | 15 |
| Propensity score | 94 |
| Prophylaxis | 106 |
| Prostate biopsy | 100, 106 |
| Prostate cancer | 57, 72, 100, 111, 126, 129 |
| Prostate cancer aggressiveness | 28 |
| Prostate needle biopsy | 138 |
| Prostate neoplasms | 138 |
| Prostate specific antigen | 100 |
| Prostate-specific antigen | 138 |
| pTa | 20 |
| Radical cystectomy | 50 |
| Radical prostatectomy | 62, 72, 138 |
| Radiotherapy | 62 |
| RCC | 76 |
| Recurrence free survival | 150 |
| Renal cell carcinoma (RCC) | 150 |
| Renal pelvis | 68 |
| Renal tumor | 94 |
| Second look | 20 |
| Second primary cancer | 144 |
| Second TURBT | 20 |
| Sedoanalgesia | 111 |
| Situs inversus totalis | 120 |
| Small molecules | 1 |
| Smoking status | 144 |
| Suprapubic pain | 161 |
| Targeted biopsy | 111 |
| Testicular adrenal rest tumor | 80 |
| Testicular cancer | 89, 156 |
| Testicular mass | 166 |
| Testis | 126 |
| Theranostics | 129 |
| Therapeutic embolization | 84 |
| Transurethral resection of prostate | 138 |
| Tuberous sclerosis | 84 |
| Urachal carcinoma | 116 |
| Urachal mass | 161 |
| Ureter | 68 |
| Ureteric metastasis | 46 |
| Urinary bladder neoplasms | 42 |
| Urinary diversion | 50 |
| Urological neoplasms | 76 |
| Urology | 1 |
| Urothelial carcinoma | 20, 68 |
| YouTube | 156 |